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Abstract
Adults with congenital heart disease (ACHD) have emerged as a new patient population 
that poses a variety of treatment and management obstacles. This chapter discusses the 
diagnosis of heart failure and treatment challenges faced by ACHD specifically address-
ing when to initiate mechanical circulatory support versus heart transplantation. It is 
evident that the ACHD population presents with a variety of unique challenges and 
considerations that still need to be explored. Addressing each of these issues will vastly 
change and improve how ACHD patients are approached from a treatment standpoint 
and ultimately provide more advantageous clinical options that can successfully handle 
the complexities presented by this population.
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1. Introduction
Over the past several decades, adults with congenital heart disease (ACHD) have emerged as 
a new type of patient population that poses a variety of treatment and management obstacles. 
In North America alone, the prevalence of ACHD is estimated to be greater than 1 million 
patients [1]. The emergence of this group can be attributed to the clinical advancements that 
have been made in addressing these congenital disorders as they present during childhood 
and has enabled over 85% of children diagnosed with CHD to survive to adulthood [2]. 
As these patients progress into adulthood, they continue to experience complications and 
medical complexities associated with their CHD. The dominant complication that the ACHD 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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population faces is the development of heart failure, and this is currently recognized as the 
leading cause of death for ACHD patients [3].
In current medical practice, the gold standard for treating end stage heart failure is heart 
transplantation. This however remains a treatment option that is limited by donor supply. 
For the past several decades, the number of heart transplants that have been performed annu-
ally in the United States is between 2000 and 2500 [4]. This supply does not meet the current 
demands of the growing heart failure population. As the prevalence of heart failure in the 
ACHD population grows, the demand for heart failure treatment will continue to increase, 
placing further strain on the already overburdened transplant system.
In addition to the concerns associated with donor supply, ACHD patients face further bur-
dens when seeking heart transplantation as a treatment option due to their medical complexi-
ties that are not currently accounted for in the guidelines established by UNOS. These include 
younger age, anatomical complexities, and decreased likelihood of an implanted mechani-
cal assist device in comparison to the non-ACHD candidates. This, in turn, leads to a lower 
urgency status, longer waitlist times, and a higher incidence of ACHD patients experiencing 
delisting due to clinical deterioration [5].
It is evident that further evaluation of the growing ACHD population is necessary in order 
to provide effective management plans for the treatment of heart failure that will account for 
their complex circumstances. This chapter discusses current medical management, associated 
treatment outcomes, and future directions in the management of ACHD patients.
2. Diagnosis
The diagnosis of heart failure in ACHD is often difficult because this population may pres-
ent with atypical signs and symptoms; however, diagnosis is facilitated by regular follow-up 
including history and physical exam, laboratory and imaging studies, and functional testing 
that is part of the management of these patients. Once a hemodynamic lesion is identified on 
imaging, correction of the lesion is usually required. If no hemodynamic lesion is present, 
patients are classified into two groups based on whether or not there is impaired ventricular 
function. Medical management of heart failure is indicated when there is impaired ventricu-
lar function without a significant hemodynamic lesion or for patients with normal ventricular 
function who are clinically symptomatic with either an elevated BNP or evidence of impair-
ment of cardiopulmonary exercise testing. Regular follow-up is indicated if BNP or exercise 
testing is normal or for clinically, asymptomatic patients with normal ventricular function [1].
3. Treatment
3.1. Medical management
Once heart failure is recognized, medical treatment consists of a cocktail of medica-
tions including diuretics, beta blockers, renin-angiotensin-aldosterone system blockers, 
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mineralocorticoid receptor antagonists, digoxin, pulmonary vasodilators, calcium channel 
blockers, and afterload reducing agents, similar to adult-onset heart failure [1]. Treatment 
is tailored based on specific physiology and is outside the scope of this chapter. Other 
interventions include implantation of a cardioverter defibrillator [6] and cardiac resynchro-
nization therapy [7].
3.2. Surgical management
Structural intervention is often required in patients with adult CHD and ranges from cath-
eter based therapy to heart transplantation depending on the etiology of CHD and presen-
tation of symptoms in adulthood. The decision to undertake surgical correction must be 
weighed carefully against medical management as survival decreases with an increase in 
the number of sternotomies [8]. Additionally, the use of blood products may cause HLA 
sensitization, impacting the potential for later heart transplant [9]. Cardiac surgery includes 
pulmonary valve/conduit replacement, closure of atrial septal defects, aortic procedures, 
repair/revision of tetralogy of Fallot, conversion to or revision of Fontan repair, and other 
valvular repair/replacements [10].
Mechanical circulatory support (MCS) assistance may be indicated for patients who develop 
acute heart failure resistant to maximal medical management. Extracorporeal membrane 
oxygenation is considered for patients who develop cardiogenic shock and often serves as 
a “bridge to decision” therapy in this patient population [11]. Unlike standard heart failure, 
ECMO is particularly useful for CHD patients who develop right ventricular failure [12]. The 
use of ECMO should be limited to patients who have not developed multi-organ failure as 
prognosis is poor in this population.
The number of chronic ventricular assist device implantations continues to increase although 
concentrated to relatively few centers [13]. Few patients with single ventricle morphology are 
implanted as most patients are classified as systemic morphological left or right ventricle [13]. 
Similar to ECMO therapy, long-term MCS is used as a bridge to transplant or candidacy and 
seldom used as destination therapy [13]. Most patients are implanted with a left VAD, but there 
is a higher proportion of patients compared to the acquired heart failure population who require 
biventricular support with either biventricular VADs or a total artificial heart [13]. Across all mor-
phologies, axial, continuous flow pumps are more commonly used; however, there is a larger 
proportion of pulsatile pumps used in the ACHD population compared with those with acquired 
heart failure [13].
Heart transplantation is considered when estimated 1-year survival is less than 80%. The deci-
sion to list for heart transplant is complex, more so than patients with acquired heart failure, 
and factors influencing this decision include anatomical considerations, presence of non-heart 
end-stage organ failure, progressive cyanosis, degree of pulmonary hypertension, and cardio-
pulmonary exercise testing [14]. Patients with single ventricle morphology present particular 
anatomical and vascular challenges, as they often require additional surgical procedures at the 
time of transplant including pulmonary artery and abnormal systemic venous return recon-
struction. Overall, patient selection is crucial for the success of heart transplant in adults with 
congenital heart disease.
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4. Current outcomes for adults with congenital heart disease
4.1. Mechanical circulatory support
In the treatment of heart failure, the emergence of mechanical circulatory assist devices has 
become a widely accepted option for individuals who either do not meet the transplant cri-
teria or as a bridge to transplantation. Despite their widespread use in non-ACHD patients, 
mechanical circulatory assist devices are not as easily applied to the ACHD population 
because many of these patients present with anatomical challenges such as single ventricles, 
vascular reconstruction of major arteries, and systemic right ventricles [2]. The complexity of 
anatomical variants in addition to the presence of comorbidities contributes to a higher peri-
operative complication rate compared with the non-ACHD population. These adverse events 
include higher rates of hepatic dysfunction, respiratory failure, renal dysfunction requiring 
dialysis, and sustained cardiac arrhythmias [13]. When compared with a matched non-ACHD 
cohort, Cedars et al. found that early survival in the first 5 months post-implantation was 
worse in the ACHD population but comparable thereafter, and functional status and quality 
of life parameters were similar in both groups. They attributed these findings to the operative 
and perioperative factors unique to the ACHD population, particularly anatomic issues and 
increased likelihood of having previous sternotomies. Overall, results suggest that MCS is a 
good option for ACHD patients with advanced heart failure despite increased peri-operative 
complications and mortality as a bridge to transplant and may be a viable option as destina-
tion therapy in the future. Outcomes after MCS implantation are shown in Table 1.
4.2. Transplantation
ACHD patients experience a variety of disadvantages when seeking transplantation as a treat-
ment for their heart failure. Issues such as anatomical concerns and immune status can impact 
their ability for transplant candidacy significantly. If these factors do not influence their abil-
ity to be placed on the transplant registry, the ACHD population experiences a higher waitlist 
mortality than non-ACHD patients. This can be attributed to factors such as ACHD patients 
typically being of a younger age and less likely to utilize mechanical circulatory assist devices 
due to clinical barriers. As a result, they may experience longer wait list periods, a greater 
incidence of death while waiting for a transplant, or delisting [5].
The outcomes for ACHD patients that are successfully transplanted vary depending on 
short-term versus long-term comparisons and are shown in Table 2. Short-term outcomes 
for ACHD patients, similar to outcomes after MCS, are worse than when compared to non-
ACHD patients: 20–30% mortality at 30 days mortality [1]. This increased mortality rate can 
potentially be explained by unique challenges associated with the ACHD population such as 
anatomical concerns and longer times of ischemia during surgery due to the need for recon-
struction during the transplant [15]. One study by Paniagua Martn et al. [16] suggests that 
the cause for this difference can be attributed to a higher incidence of primary graft failure in 
ACHD patients. Despite increased peri-operative mortality, the long-term survival for ACHD 
patients is outstanding, with a median survival of greater than 20 years [2].
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Source Study description Purpose Results
VanderPluym 
et al. [13]
Data entered into the 
Interagency Registry for 
Mechanically Assisted 
Circulatory Support 
(INTERMACS) from June 2006 
to December 2015 was utilized. 
The 126 ACHD patients 
were categorized as follows: 
63 systemic morphologic 
left ventricle, 45 systemic 
morphologic right ventricle, 
and 17 single ventricle.
To compare mortality 
between ACHD and non 
ACHD patients after 
device implantation.
The survival rate was similar between 
ACHD and non-ACHD patients with 
LVAD’s.
Maly et al. [17] Five adult patients with 
systemic right ventricular 
failure after a Mustard 
operation were implanted with 
a HeartMate II VAD.
To collect data on 
utilizing LVAD’s as 
bridge to transplantation 
devices in patients with 
previously palliated 
transposition of great 
arteries.
Heart failure symptoms improved in 
all patients; therefore, a VAD may be 
a suitable treatment option in bridge 
to transplant for patients who are 
severely ill.
Everitt et al. [18] An analysis of 9722 adults, 
314 of which were diagnoses 
with ACHD was conducted 
to identify key differences in 
listing status and outcomes.
To analyze waitlist 
outcomes for ACHD 
versus non ACHD 
patients in heart 
transplantation.
Adults with CHD were much less 
likely to have a VAD (5 versus 
14%) and were more likely to be 
given a lower urgency status. These 
patients were also more likely to 
experience cardiovascular related 
death with waiting to undergo heart 
transplantation (60 versus 40%). 
The utilization of VAD’s should be 
explored to determine if survival for 
ACHD patients can be improved.
Shah et al. [19] A retrospective analysis 
of six ACHD patients who 
underwent VAD implantation.
To provide data for 
ACHD patients with VAD 
implantation.
Five patients survived to discharge: 
one patient was successfully 
transplanted, one patient survived 
262 days; one patient received 
988 days of therapy while awaiting 
transplantation as of December 1, 
2012; and two patients who received 
VADs as destination therapy received 
577 and 493 days and were still 
alive as of December 1, 2012. VAD 
implantation is a viable option for 
therapy in ACHD patients in either 
bridge to transplant or bridge to 
destination therapy.
Newcomb et al. 
[20]
An ACHD patient with 
failing Fontan circulation 
was implanted with an LVAD 
device and went on to have a 
successful heart transplantation 
5 months later.
A case study that 
discusses the outcome of 
an LVAD implantation in 
an ACHD patient with a 
failing Fontan circulation 
as bridge to transplant 
therapy.
This case report suggests that LVAD’s 
can become useful in patients with 
ACHD, particularly those with 
failing Fontan circulation as either 
bridge to transplant or bridge to 
destination therapy.
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Source Sample/study description Purpose Results
Irving et al. 
[26]
Outcomes were reviewed from 
38 cardiac transplants performed 
in 37 patients from 1988 to 2009 
using medical records and 
transplant databases. 41% had 
univentricular and 59% had 
biventricular physiology.
To explore data on outcomes 
of cardiac transplantation in 
the ACHD patient group.
Operative mortality for ACHD 
patients following cardiac 
transplantation is higher than for 
other diagnostic groups. However, 
long term survival is noted to 
be good and comparable to non 
ACHD patients.
Source Study description Purpose Results
Morris et al. [21] A presentation of a case in 
which LVAD implantation was 
utilized as therapy option in an 
ACHD patient that presented 
with failure of the systemic 
ventricle.
A case study of LVAD 
implantation in an ACHD 
patient.
Utilization of the LVAD therapy 
significantly improved the patients 
cyanosis and ventricular function. 
This suggests that patients with 
ACHD could benefit from utilizing 
LVAD therapy.
Stewart et al. [22] Two ACHD patients were 
successfully bridged to 
transplantation utilizing LVAD 
therapy. Their deterioration 
leading to the need for 
transplant can be attributed 
to their deteriorating right 
ventricular failure.
To explain the case 
reports of two ACHD 
patients who received 
LVAD bridge to 
transplant therapy.
This report suggests that LVAD 
therapy is a viable option for bridge 
to transplantation in ACHD patients 
that present with right ventricular 
failure.
Gelow et al. [23] A retrospective study of 1250 
ACHD patients reported in the 
UNOS database from 1985 to 
2010 in which these patients 
were compared to non –ACHD 
patients in terms of VAD use 
at listing, listing status, status 
upgrades and reasons for 
upgrades.
To determine the 
relationship that 
exists between VAD 
implantation and 
successful transplantation 
in patients that are listed 
for heart transplant.
It was noted that the use of VAD’s in 
ACHD patient was less at both the 
time of listing and transplantation. 
This decreased usage of VAD therapy 
in ACHD patients contributes 
to lower listing status and organ 
allocation.
Joyce et al. [24] Three adult patients that 
had congenitally corrected 
transposition of the great 
arteries underwent LVAD 
implantation as a therapy 
option for their end stage heart 
failure.
A case report of three 
ACHD patients that 
underwent LVAD 
implantation.
LVAD implantation can be 
successfully completed in ACHD 
patients when placed under 
echocardiographic guidance. This 
offers an additional therapy option 
for ACHD patients.
Maxwell et al. 
[25]
Data collected from September 
1987 to September 2012 by 
the Scientific Registry of 
Transplant Recipients was 
utilized to compare the 
following between MCS and 
non-MCS ACHD patient 
populations: procedural, 
outcome and survival.
To analyze the 
pretransplant effects of 
mechanical circulatory 
support on posttransplant 
outcomes in the ACHD 
population.
In the ACHD patient population, 
those with MCS are associated with 
higher transfusion rates and length of 
stay however, they do not have less 
favorable outcomes post-transplant 
when compared to non-MCS ACHD 
patients.
Table 1. Outcomes after mechanical circulatory support device implantation in adults with congenital heart disease.
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Source Sample/study description Purpose Results
Patel et al. [27] Data reported to UNOS from 
1987 to 2006 was reviewed 
and categorized to compare 
adults with CHD versus 
other diagnoses in heart 
transplantations. 2% of the 
individuals in this study period 
had CHD.
To evaluate the post 
transplantation prognosis in 
adults with CHD.
The 30-day mortality rate is 
elevated in the ACHD population: 
16 versus 6%. However, there is 
not a statistical significance in the 
5 and 10-year survival rates for 
ACHD patients in comparison to 
non-ACHD patients.
Taylor et al. 
[28]
Data from heart transplantations 
performed from 2001 to 2003 
was utilized to calculate survival 
rates by the Kaplan–Meier 
method. Adults with CHD 
represented 2.7% of the cohort.
To evaluate the survival 
outcomes for patients post 
heart transplantation.
Having a diagnosis of ACHD is one 
of the most powerful predictors of 
1-year mortality. But at 10 years it is 
associated with a marked survival 
advantage conditional on a 3-year 
survival independent of age.
Lamour et al. 
[29]
The post-transplantation 
outcomes for 24 adults with 
CHD were analyzed utilizing 
the Kaplan–Meier statistical 
method to estimate survival 
functions for patients with CHD 
versus all others and patients 
with CHD versus matched 
controls.
To analyze the survival rate 
of adult patients with CHD 
post cardiac transplantation 
in comparison in those 
without CHD.
The survival rate for patients with 
ACHD post-transplantation was 
79% at 1 year and 60% at 5 years. A 
difference between this population 
and the control populations was 
not present.
Davies et al. 
[8]
A retrospective study of 
patients listed for primary 
transplantation between 1995 
and 2009 was conducted. 2.5% 
of these patients were adults 
with CHD.
To evaluate the survival of 
adults with CHD after listing 
and transplantation.
The early mortality rate (30 day) 
among ACHD patients was high 
(reoperation 18.9 versus 9.6%; 
nonreoperation 16.6 versus 6.3%), 
but at 10 years the survival rate 
was equivalent with non-ACHD 
patients (53.8 versus 53.6%)
Bhama et al. 
[30]
A retrospective analysis was 
conducted from January 2001 to 
February 2011. 19 patients with 
ACHD were compared to 428 
patients with non-ACHD who 
underwent transplantation.
To evaluate the survival 
outcomes of cardiac 
transplantation in adults 
with CHD in a contemporary 
cohort.
There was no significant difference 
in survival of ACHD versus non-
ACHD at 30 days (89 versus 92%), 




A review of heart 
transplantation patients from 
1990 to 2008 reported to UNOS 
was conducted. A total of 8496 
patients were evaluated, of 
which 575 had ACHD.
To investigate outcomes and 
risk factors for mortality 
and retransplantation for 
the ACHD population in 
comparison to the non-
ACHD population.
The overall post-transplantation 
mortality and retransplantation 
rates were significantly higher for 
patients with ACHD mainly due to 
an early hazard phase.
Burchill et al. 
[32]
A retrospective study was 
conducted on patients who 
were identified in the registry 
of ISHLT between 1985 and 
2010. The Kaplan–Meier method 
was used to conduct a survival 
comparison. 2.2% of patients 
transplanted in this cohort had a 
diagnosis of ACHD.
To examine survival, causes 
of death and predictors 
of early (<1 year), mid-
term (1–5 years) and later 
(0.5 years) mortality in 
ACHD patients who received 
cardiac transplants.
Early mortality rates for the ACHD 
population was high in comparison 
to the non-ACHD transplant 
recipients (10 versus 4%). The 
long-term survival rates for ACHD 
patients who survived the early 
hazard phase was superior to the 
non-ACHD patients.
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Regardless of this data, outcomes for patients with ACHD after transplantation vary depend-
ing on their initial diagnosis. As there are a variety of clinical manifestations of ACHD, assess-
ing prognostic values remains challenging and therefore individuals should be evaluated 
thoroughly prior to transplant consideration.
5. Conclusion
Further investigation into the ACHD population is essential in order to effectively manage 
their unique medical concerns as this patient group continues to expand. This investigation 
must occur from multiple points in order to ensure the variety of distinct challenges presented 
by this population are adequately addressed. Specifically, there are four areas this chapter 
suggests future research efforts should focus on in order to provide the most advantageous 
information for medical management:
• The cause of increased early mortality rates in heart transplant operations for ACHD patients. 
After thorough review of the current literature, it is evident that ACHD patients experience 
Source Sample/study description Purpose Results
Paniagua 
Martin et al. 
[16]
Survival outcomes in a total of 
3166 patients were included: 
1888 IHD, 1223 IDCM, and 55 
ACHD.
To analyze the survival 
probability between different 
subgroups with ACHD.
The early mortality rating 
associated with ACHD can 
primarily be attributed to the 
presence of primary graft failure. 
The frequency of primary graft 
failure in ACHD was 23%, versus 
17% in IHD and 13% in IDCM. The 
following is the frequency of early 
mortality rates: 25% CHD, 14% 
IDCM, 16% IHD.
Singh et al. 
[33]
Adults who underwent heart 
transplantation in the United 
States between January 2007 
and June 2009 were utilized 
to determine and validate the 
risk prediction model. This 
efficiency of this model was 
further assessed by evaluating 
the performance in patients 
from July 2009 to October 2010 
receiving heart transplants.
To develop a risk prediction 
model for posttransplant in 
hospital mortality in heart 
transplant patients.
The model determined that the 
ACHD diagnosis is correlated 
with an odds ratio of 4.18 for early 




A comparison among in hospital 
deaths between ACHD patients 
that possessed either 1 V or 
2 V anatomy was conducted 
retrospectively from 1993 to 
2007 through data gathered 
in the Nationwide Inpatient 
Sample (NIS).
To determine if there is an 
associated with early death 
post heart transplantation 
in patients who possess 1 V 
anatomy in ACHD.
ACHD patients that possess 1 V 
anatomy are associated with a 
higher death incidence post heart 
transplantation. Transplantation 
registries should include specific 
ACHD diagnoses due to the 
evident difference in associated 
outcomes.
Table 2. Outcomes after heart transplantation in adults with congenital heart disease.
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higher early mortality rate post heart transplantation in comparison to non-ACHD patients. 
However, at this point in time little research has been focused on identifying the clinical 
source for this mortality contrast. It is essential that research efforts focus on seeking out the 
root of this disparity in order to work towards minimizing the presence of this current com-
plex outcome. Doing so will supply the medical community with more accurate predictors 
of mortality when seeking heart transplantation as treatment for these patients and provide 
better outcomes to those who undergo this type of medical management.
• Determining the appropriate timing/type of interventions to utilize for this clinically diverse 
group. Due to the clinical diversity that exists within the ACHD patient populations apply-
ing standardized treatment regimens remains challenging. Case studies exploring how 
to effectively manage different anatomical morphologies currently exist but this aspect of 
research still remains relatively unexamined and information specifically regarding timing 
is rather limited. Increasing the knowledge in terms of how to effectively approach treat-
ment in ACHD patients in terms of when and how to intervene will assist in decreasing the 
complexity of approaching a therapy regimen and provide stronger evidence to provide 
the best possible clinical outcomes for these patients.
• Re-evaluating how ACHD patients are listed into the transplant registries. With the cur-
rent listing guidelines ACHD patients are at a significant disadvantage in terms of their 
likelihood of being successfully transplanted. As of now, ACHD patients are more likely to 
experience a lower listing status with their initial listing than non-ACHD patients. In addi-
tion, ACHD patients experience a high rate of delisting after 1 year due to a decline in their 
worsening condition. These patients are placed at an even further disadvantage because 
they may not be candidates for mechanical circulatory support due to anatomical con-
straints. Therefore, they are unable to utilize the placement of these devices to prolong their 
survival to successfully reach transplantation, or utilize the benefits of attaining a higher 
listing status associated with these interventional therapies. The current listing criteria for 
heart transplantation is a cause of serious concern when considering ethical and effective 
medical management for patients with ACHD. There is an urgent need for re-evaluation 
of these current guidelines to occur in order to take into consideration the unique medical 
challenges presented by this growing population that will continue to rely on heart trans-
plantation as one of their main treatment possibilities in the future.
• Exploring the use of MCS as destination therapy in addition to bridge to transplantation. 
The utilization of these devices for treatment in ACHD patients has previously focused 
on their usage as bridge to transplant therapy. However, with the increasing demand for 
heart transplantation, it is imperative that other therapy options are considered for ACHD 
patients. More recently, the use of MCS has been considered as destination therapy for 
this group of patients. Current research indicates that there is potential for pursuing this 
line of treatment option for a variety of ACHD subgroups. Doing so would provide an 
effective treatment option for these patients and relieve some of the current burden on the 
transplant system.
It is evident that the ACHD population presents with a variety of unique challenges and 
considerations that still need to be explored. Addressing each of these areas mentioned above 
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will vastly change and improve how ACHD patients are approached from a treatment stand-
point and ultimately provide more advantageous clinical options that can successfully handle 
the complexities presented by this population.
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